HIV molecular immunology database

 

Search CTL/CD8+ T-Cell Epitope Database

Found 5 matching records:

Displaying record number 58642

HXB2 Location Gag(77-85)
p17(77-85)
DNA(1018..1044)
Gag Epitope Map
Author Location Gag(77-85)
Epitope SLYNTVATL Epitope Alignment
SLYNTVATL epitope logo
Epitope Name Gag77-85
Subtype B
Species (MHC/HLA) human(A*0201)
Immunogen peptide-HLA interaction
Country United States
Experimental methods Chromium-release assay
Keywords enhancing activity

Notes

References

Dupuis1997 M. Dupuis, M. V. Peshwa, C. Benike, S.K> Kundu, E. G. Engleman, W. C. Van Schooten, and T. C. Merigan. Allogeneic Dendritic Cell Induction of HIV-Specific Cytotoxic T Lymphocyte Responses from T Cells of HIV Type 1-Infected and Uninfected Individuals. AIDS Res. Hum. Retroviruses, 13:33-39, 1997. The potential benefit of T cell-based vaccination for HIV-1 infection remains to be determined. Cytotoxic T lymphocytes (CTLs) appear to clear substantial populations of HIV-1 virus in vivo, although CTL activity may contribute to the decline in CD4+ T cell count observed in the course of the disease. To investigate further the role of specific CTL responses in the control of HIV-1 replication, we raised primary CTL lines against a panel of conserved HIV-1 epitopes using blood-derived dendritic cells as antigen-presenting cells (APCs). Specific primary human CTL responses were induced against HLA-A*0201-restricted peptides with dendritic cells from HIV-1-seronegative donors. This method of immunization elicited cytotoxic activities capable of recognizing endogenously processed antigen. The CTL induction protocol was extended in order to explore the capacity of HLA-matched allogeneic dendritic cells to evoke novel CTL responses in T cells from an HIV-seropositive asymptomatic individual. Allogeneic peptide-pulsed dendritic cells from a healthy sibling were capable of eliciting a CTL response directed against an HIV epitope (env814: SLLNATDIAV) that was initially not detected in the CTL effector population of the HIV-1- infected patient. The possibility of manipulating CTL specificity directed against multiple conserved HIV-1 epitopes represents a significant step in the evaluation of T cell-based vaccination for treatment of disease. PubMed ID: 8989425. Show all entries for this paper.


Displaying record number 58640

HXB2 Location Pol(464-472)
RT(309-317)
DNA(3474..3500)
Pol Epitope Map
Author Location Pol(464-472)
Epitope ILKEPVHGV Epitope Alignment
ILKEPVHGV epitope logo
Epitope Name Pol464-472
Subtype B
Species (MHC/HLA) human(A*0201)
Immunogen peptide-HLA interaction
Country United States
Experimental methods Chromium-release assay
Keywords enhancing activity

Notes

References

Dupuis1997 M. Dupuis, M. V. Peshwa, C. Benike, S.K> Kundu, E. G. Engleman, W. C. Van Schooten, and T. C. Merigan. Allogeneic Dendritic Cell Induction of HIV-Specific Cytotoxic T Lymphocyte Responses from T Cells of HIV Type 1-Infected and Uninfected Individuals. AIDS Res. Hum. Retroviruses, 13:33-39, 1997. The potential benefit of T cell-based vaccination for HIV-1 infection remains to be determined. Cytotoxic T lymphocytes (CTLs) appear to clear substantial populations of HIV-1 virus in vivo, although CTL activity may contribute to the decline in CD4+ T cell count observed in the course of the disease. To investigate further the role of specific CTL responses in the control of HIV-1 replication, we raised primary CTL lines against a panel of conserved HIV-1 epitopes using blood-derived dendritic cells as antigen-presenting cells (APCs). Specific primary human CTL responses were induced against HLA-A*0201-restricted peptides with dendritic cells from HIV-1-seronegative donors. This method of immunization elicited cytotoxic activities capable of recognizing endogenously processed antigen. The CTL induction protocol was extended in order to explore the capacity of HLA-matched allogeneic dendritic cells to evoke novel CTL responses in T cells from an HIV-seropositive asymptomatic individual. Allogeneic peptide-pulsed dendritic cells from a healthy sibling were capable of eliciting a CTL response directed against an HIV epitope (env814: SLLNATDIAV) that was initially not detected in the CTL effector population of the HIV-1- infected patient. The possibility of manipulating CTL specificity directed against multiple conserved HIV-1 epitopes represents a significant step in the evaluation of T cell-based vaccination for treatment of disease. PubMed ID: 8989425. Show all entries for this paper.


Displaying record number 58641

HXB2 Location Pol(956-965)
Integrase(241-250)
DNA(4950..4979)
Pol Epitope Map
Author Location Pol(956-964)
Epitope LLWKGEGAVV Epitope Alignment
LLWKGEGAVV epitope logo
Epitope Name Pol956-964
Subtype B
Species (MHC/HLA) human(A*0201)
Immunogen peptide-HLA interaction
Country United States
Experimental methods Chromium-release assay
Keywords enhancing activity

Notes

References

Dupuis1997 M. Dupuis, M. V. Peshwa, C. Benike, S.K> Kundu, E. G. Engleman, W. C. Van Schooten, and T. C. Merigan. Allogeneic Dendritic Cell Induction of HIV-Specific Cytotoxic T Lymphocyte Responses from T Cells of HIV Type 1-Infected and Uninfected Individuals. AIDS Res. Hum. Retroviruses, 13:33-39, 1997. The potential benefit of T cell-based vaccination for HIV-1 infection remains to be determined. Cytotoxic T lymphocytes (CTLs) appear to clear substantial populations of HIV-1 virus in vivo, although CTL activity may contribute to the decline in CD4+ T cell count observed in the course of the disease. To investigate further the role of specific CTL responses in the control of HIV-1 replication, we raised primary CTL lines against a panel of conserved HIV-1 epitopes using blood-derived dendritic cells as antigen-presenting cells (APCs). Specific primary human CTL responses were induced against HLA-A*0201-restricted peptides with dendritic cells from HIV-1-seronegative donors. This method of immunization elicited cytotoxic activities capable of recognizing endogenously processed antigen. The CTL induction protocol was extended in order to explore the capacity of HLA-matched allogeneic dendritic cells to evoke novel CTL responses in T cells from an HIV-seropositive asymptomatic individual. Allogeneic peptide-pulsed dendritic cells from a healthy sibling were capable of eliciting a CTL response directed against an HIV epitope (env814: SLLNATDIAV) that was initially not detected in the CTL effector population of the HIV-1- infected patient. The possibility of manipulating CTL specificity directed against multiple conserved HIV-1 epitopes represents a significant step in the evaluation of T cell-based vaccination for treatment of disease. PubMed ID: 8989425. Show all entries for this paper.


Displaying record number 58638

HXB2 Location gp160(121-129)
gp120(121-129)
DNA(6585..6611)
gp160 Epitope Map
Author Location Env(120-128)
Epitope KLTPLCVTL Epitope Alignment
KLTPLCVTL epitope logo
Epitope Name Env120-128
Subtype B
Species (MHC/HLA) human(A*0201)
Immunogen peptide-HLA interaction
Country United States
Experimental methods Chromium-release assay
Keywords enhancing activity

Notes

References

Dupuis1997 M. Dupuis, M. V. Peshwa, C. Benike, S.K> Kundu, E. G. Engleman, W. C. Van Schooten, and T. C. Merigan. Allogeneic Dendritic Cell Induction of HIV-Specific Cytotoxic T Lymphocyte Responses from T Cells of HIV Type 1-Infected and Uninfected Individuals. AIDS Res. Hum. Retroviruses, 13:33-39, 1997. The potential benefit of T cell-based vaccination for HIV-1 infection remains to be determined. Cytotoxic T lymphocytes (CTLs) appear to clear substantial populations of HIV-1 virus in vivo, although CTL activity may contribute to the decline in CD4+ T cell count observed in the course of the disease. To investigate further the role of specific CTL responses in the control of HIV-1 replication, we raised primary CTL lines against a panel of conserved HIV-1 epitopes using blood-derived dendritic cells as antigen-presenting cells (APCs). Specific primary human CTL responses were induced against HLA-A*0201-restricted peptides with dendritic cells from HIV-1-seronegative donors. This method of immunization elicited cytotoxic activities capable of recognizing endogenously processed antigen. The CTL induction protocol was extended in order to explore the capacity of HLA-matched allogeneic dendritic cells to evoke novel CTL responses in T cells from an HIV-seropositive asymptomatic individual. Allogeneic peptide-pulsed dendritic cells from a healthy sibling were capable of eliciting a CTL response directed against an HIV epitope (env814: SLLNATDIAV) that was initially not detected in the CTL effector population of the HIV-1- infected patient. The possibility of manipulating CTL specificity directed against multiple conserved HIV-1 epitopes represents a significant step in the evaluation of T cell-based vaccination for treatment of disease. PubMed ID: 8989425. Show all entries for this paper.


Displaying record number 58639

HXB2 Location gp160(813-822)
gp41(302-311)
DNA(8661..8690)
gp160 Epitope Map
Author Location Env(814-823)
Epitope SLLNATDIAV Epitope Alignment
SLLNATDIAV epitope logo
Epitope Name Env814
Subtype B
Species (MHC/HLA) human(A*0201)
Immunogen peptide-HLA interaction, vaccine
Country United States
Experimental methods Chromium-release assay
Keywords dendritic cells, enhancing activity

Vaccine Details

Vaccine type vaccinia
Vaccine strain B clade
Vaccine component Env

Notes

References

Dupuis1997 M. Dupuis, M. V. Peshwa, C. Benike, S.K> Kundu, E. G. Engleman, W. C. Van Schooten, and T. C. Merigan. Allogeneic Dendritic Cell Induction of HIV-Specific Cytotoxic T Lymphocyte Responses from T Cells of HIV Type 1-Infected and Uninfected Individuals. AIDS Res. Hum. Retroviruses, 13:33-39, 1997. The potential benefit of T cell-based vaccination for HIV-1 infection remains to be determined. Cytotoxic T lymphocytes (CTLs) appear to clear substantial populations of HIV-1 virus in vivo, although CTL activity may contribute to the decline in CD4+ T cell count observed in the course of the disease. To investigate further the role of specific CTL responses in the control of HIV-1 replication, we raised primary CTL lines against a panel of conserved HIV-1 epitopes using blood-derived dendritic cells as antigen-presenting cells (APCs). Specific primary human CTL responses were induced against HLA-A*0201-restricted peptides with dendritic cells from HIV-1-seronegative donors. This method of immunization elicited cytotoxic activities capable of recognizing endogenously processed antigen. The CTL induction protocol was extended in order to explore the capacity of HLA-matched allogeneic dendritic cells to evoke novel CTL responses in T cells from an HIV-seropositive asymptomatic individual. Allogeneic peptide-pulsed dendritic cells from a healthy sibling were capable of eliciting a CTL response directed against an HIV epitope (env814: SLLNATDIAV) that was initially not detected in the CTL effector population of the HIV-1- infected patient. The possibility of manipulating CTL specificity directed against multiple conserved HIV-1 epitopes represents a significant step in the evaluation of T cell-based vaccination for treatment of disease. PubMed ID: 8989425. Show all entries for this paper.


Questions or comments? Contact us at immuno@lanl.gov
 
Operated by Los Alamos National Security, LLC, for the U.S. Department of Energy's National Nuclear Security Administration
Copyright © 2006-2017 LANS LLC All rights reserved | Disclaimer/Privacy

Dept of Health & Human Services Los Alamos National Institutes of Health